Entrada Therapeutics (TRDA) director awarded 19,000 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Entrada Therapeutics director Radhakrishnan Maha received a grant of 19,000 stock options. Each option allows the purchase of one share of common stock at an exercise price of $5.97 per share and was granted at no cost.
The options vest and become exercisable on the earlier of the one-year anniversary of June 10, 2026 or Entrada’s next annual meeting of stockholders, and expire on June 10, 2036. After this grant, Maha holds 19,000 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Radhakrishnan Maha
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 19,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 19,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 19,000 options
Exercise price: $5.97 per share
Underlying shares: 19,000 shares
+2 more
5 metrics
Options granted
19,000 options
Stock Option (Right to Buy) granted on June 10, 2026
Exercise price
$5.97 per share
Exercise price for underlying common stock
Underlying shares
19,000 shares
Common Stock underlying the options
Post-grant derivative holdings
19,000 options
Total stock options held after this grant
Expiration date
June 10, 2036
Option expiration for the grant
Key Terms
Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 5.9700"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting of stockholders financial
"the Issuer's next annual meeting of stockholders."
FAQ
What insider transaction did Entrada Therapeutics (TRDA) report for Radhakrishnan Maha?
Entrada Therapeutics reported that director Radhakrishnan Maha received a grant of 19,000 stock options. These options give the right to buy common shares at $5.97 each, were granted at no cost, and vest based on time or the next shareholder meeting.
What is the exercise price of the new Entrada Therapeutics (TRDA) stock options?
The granted stock options have an exercise price of $5.97 per share. This means Maha can later buy Entrada Therapeutics common stock at $5.97, regardless of the future market price, once the options vest and before they expire in 2036.
When do Radhakrishnan Maha’s Entrada Therapeutics (TRDA) options vest?
The 19,000 stock options vest on the earlier of the one-year anniversary of June 10, 2026 or Entrada Therapeutics’ next annual meeting of stockholders. Vesting must occur before the options become exercisable for purchasing common shares at the fixed price.
When do the newly granted Entrada Therapeutics (TRDA) stock options expire?
The stock options granted to Radhakrishnan Maha expire on June 10, 2036. After that date, any unexercised options are no longer valid, so they must be exercised between vesting and this expiration date to acquire Entrada Therapeutics common stock.
How many Entrada Therapeutics (TRDA) options does Radhakrishnan Maha hold after this grant?
After the reported grant, Radhakrishnan Maha holds 19,000 stock options directly. Each option is linked to one share of Entrada Therapeutics common stock, giving him a potential future claim on 19,000 shares if all options eventually vest and are exercised.